Kan Maxim, Gall Julia A, Latypov Alisher, Gray Robert, Bakpayev Marat, Alisheva Djamila, Rakhmatova Khursheda, Sadieva Aigul S
Population Services International, Central Asian Republics, Almaty, Kazakhstan.
The Central Asia Program, The Elliott School of International Affairs, The Institute for European, Russian, and Eurasian Studies, The George Washington University, Washington, DC, USA; Global Health Research Center of Central Asia, Columbia University, New York, NY, USA.
Int J Drug Policy. 2014 Nov;25(6):1221-6. doi: 10.1016/j.drugpo.2014.01.005. Epub 2014 Jan 23.
Opioid overdose (OD) is a major cause of mortality among people who inject drugs (PWID) in Central Asia, and distribution of naloxone, an opioid antagonist, can effectively prevent these deaths. However, little is known about the use and wastage of distributed naloxone ampoules. Having reliable data on wastage rates is critical for accurately calculating the health impact of naloxone distribution projects targeting PWID.
In 2011, Population Services International (PSI) launched two pilot naloxone distribution programs in Kyrgyzstan (pharmacy-based approach) and Tajikistan (community-based approach). PWID were trained on OD prevention and naloxone use. Upon returning for more ampoules, the PWID completed a brief survey on their OD experience and naloxone use. 158 respondents in Kyrgyzstan and 59 in Tajikistan completed the questionnaire. Usage and wastage rates were calculated based on responses. A four-year model wastage rate that takes into account the shelf life of naloxone for both countries was then calculated.
51.3% of respondents in Kyrgyzstan and 91.5% in Tajikistan reported having ever experienced an OD. 82.9% of respondents in Kyrgyzstan and all respondents in Tajikistan had ever witnessed an OD. Out of these PWID who experienced or witnessed OD, 81.5% in Kyrgyzstan and 59.3% in Tajikistan reported having been injected with naloxone, and 83.2% in Kyrgyzstan and 50.9% in Tajikistan reported injecting another individual with naloxone. Of ampoules received, 46.5% in Kyrgyzstan and 78.1% in Tajikistan were used. In both countries, 3.1% of these ampoules were wasted. The four-year model wastage rates for Kyrgyzstan and Tajikistan were found to be 13.8% and 3.9% respectively.
Findings indicate that a high proportion of naloxone distributed to PWID is used in actual OD incidents, with low wastage rates in both countries. Expanding these distribution models can potentially create more positive health outcomes for PWID in Central Asia.
阿片类药物过量(OD)是中亚注射吸毒者(PWID)死亡的主要原因,而阿片类拮抗剂纳洛酮的分发可有效预防这些死亡。然而,对于已分发的纳洛酮安瓿的使用和浪费情况知之甚少。掌握可靠的浪费率数据对于准确计算针对注射吸毒者的纳洛酮分发项目对健康的影响至关重要。
2011年,国际人口服务组织(PSI)在吉尔吉斯斯坦(基于药房的方法)和塔吉克斯坦(基于社区的方法)启动了两项纳洛酮分发试点项目。对注射吸毒者进行了阿片类药物过量预防和纳洛酮使用方面的培训。在他们回来领取更多安瓿时,注射吸毒者完成了一份关于其阿片类药物过量经历和纳洛酮使用情况的简短调查。吉尔吉斯斯坦的158名受访者和塔吉克斯坦的59名受访者完成了问卷。根据回答计算使用和浪费率。然后计算了一个考虑到两国纳洛酮保质期的四年模型浪费率。
吉尔吉斯斯坦51.3%的受访者和塔吉克斯坦91.5%的受访者报告曾经历过阿片类药物过量。吉尔吉斯斯坦82.9%的受访者和塔吉克斯坦的所有受访者都曾目睹过阿片类药物过量。在这些经历过或目睹过阿片类药物过量的注射吸毒者中,吉尔吉斯斯坦81.5%的人和塔吉克斯坦59.3%的人报告曾接受过纳洛酮注射,吉尔吉斯斯坦83.2%的人和塔吉克斯坦50.9%的人报告曾给他人注射过纳洛酮。在收到的安瓿中,吉尔吉斯斯坦46.5%的安瓿和塔吉克斯坦78.1%的安瓿被使用。在两国,这些安瓿中有3.1%被浪费。吉尔吉斯斯坦和塔吉克斯坦的四年模型浪费率分别为13.8%和3.9%。
研究结果表明,分发给注射吸毒者的纳洛酮中有很大一部分用于实际的阿片类药物过量事件,两国的浪费率都很低。扩大这些分发模式可能会为中亚的注射吸毒者带来更多积极的健康成果。